Download MendeleyDevelopment and characterization of a fully human antibody targeting SCF/c-kit signaling.
Kim, J.O., Kim, H.N., Kim, K.H., Baek, E.J., Park, J.Y., Ha, K., Heo, D.R., Seo, M.D., Park, S.G.(2020) Int J Biol Macromol 159: 66-78
- PubMed: 32437800
- DOI: https://doi.org/10.1016/j.ijbiomac.2020.05.045
- Primary Citation of Related Structures:
6LUN - PubMed Abstract:
CD117/c-kit, a tyrosine kinase receptor, plays a critical role in hematopoiesis, pigmentation, and fertility. The overexpression and activation of c-kit are thought to promote tumor growth and have been reported in various cancers, including leukemia, glioblastoma and mastocytosis. To disrupt the SCF/c-kit signaling axis in cancer, we generated a c-kit antagonist human antibody (NN2101) that binds to domain 2/3 of c-kit. This completely blocked the SCF-mediated phosphorylation of c-kit and inhibited TF-1 cell proliferation, erythroleukemia. In addition, the examination of binding affinity using surface plasmon resonance (SPR) assay showed that NN2101 can bind to c-kit of monkeys (K D = 2.92 × 10 -10 M), rats (K D = 1.68 × 10 -6 M), mice (K D = 11.5 × 10 -9 M), and humans (K D = 2.83 × 10 -12 M). We showed that NN2101 does not cause antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. The immunogenicity of NN2101 was similar to that of bevacizumab. Furthermore, the crystal structure of NN2101 Fab was determined and the structure of NN2101 Fab:c-kit complex was modeled. Structural information, as well as mutagenesis results, revealed that NN2101 can bind to the SCF-binding regions of c-kit. Collectively, we generated a c-kit neutralizing human antibody (NN2101) for the treatment of erythroleukemia and characterized its biophysical properties. NN2101 can potentially be used as a therapeutic antibody to treat different cancers.
Organizational Affiliation:
College of Pharmacy and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 World Cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16499, Republic of Korea.
